Harrow Inc - 11.875% NT REDEEM 31/12/2027 USD 25
HROWM
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.39B
Close$
$-21.51
182.6% downside
Current Fair Value
182.6% downsideOvervalued by 182.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.39 Billion |
|---|---|
| Enterprise Value | $1.61 Billion |
| Dividend Yield | $2.97 (-) |
| Earnings per Share | $-0.14 |
| Beta | 0.14 |
| Outstanding Shares | 37,350,401 |
Return
| Return on Equity | -244.91% |
|---|---|
| Return on Assets | -8.93% |
| Return on Invested Capital | -7.37% |
Valuation & Multiples
| P/E Ratio | -37.55 |
|---|---|
| PEG | 8.42 |
| Price to Sales | 3.72 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.83 |
| Enterprise Value to EBIT | -69.31 |
| Enterprise Value to Net Income | -44 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 19.79 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 2, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Harrow Health Inc
125 employeesHarrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions...